半乳糖凝集素-3参与IgA肾病发病机制
该研究探讨半乳糖凝集素-3(Gal-3)在IgA肾病(IgAN)发病中的作用。在IgAN患者及多种IgAN小鼠模型中,肾脏Gal-3表达显著增强且与疾病严重程度相关。Gal-3敲除可改善被动IgAN模型小鼠的蛋白尿、肾功能和肾脏病理,抑制NLRP3炎症小体并增强自噬;Gal-3竞争性抑制剂可恢复肾功能并改善肾脏病变。
要点
- IgAN患者及小鼠模型肾脏Gal-3表达显著增强,且与疾病严重程度相关。
- Gal-3敲除改善被动IgAN模型小鼠蛋白尿、肾功能及肾脏病理。
- Gal-3通过激活NLRP3炎症小体和促进Th17细胞分化参与IgAN发病。
核心结论
- Gal-3通过激活NLRP3炎症小体和促进Th17细胞分化参与IgA肾病发病,靶向Gal-3可能成为新治疗策略。
研究设计与样本
- 研究检测IgAN患者肾脏Gal-3表达,并在TEPC-15杂交瘤来源IgA诱导的被动和自发「grouped」ddY IgAN小鼠模型中验证。
主要发现
- IgAN患者肾脏Gal-3表达显著增强。
- 在被动和自发「grouped」ddY IgAN模型中,Gal-3在肾小球、肾小球周围区域及部分肾小管中的表达随疾病严重程度明显增加。
- 被动IgAN模型中Gal-3敲除显著改善蛋白尿、肾功能并减轻肾脏病理严重程度,包括中性粒细胞浸润减少和肾引流淋巴结Th17细胞分化降低,同时调节性T细胞百分比增加。
- Gal-3敲除抑制NLRP3炎症小体、增强自噬并改善肾脏炎症和纤维化。
- 给予6-de-O-sulfated, N-acetylated低分子量肝素(竞争性Gal-3结合抑制剂)可恢复被动IgAN小鼠肾功能并改善肾脏病变。
临床怎么用
- 靶向Gal-3(如使用竞争性Gal-3结合抑制剂)可能为IgA肾病提供新的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgA nephropathy (IgAN) is the most common type of glomerulonephritis that frequently progresses to kidney failure. However, the molecular pathogenesis underlying IgAN remains largely unknown. Here, we investigated the role of galectin-3 (Gal-3), a galactoside-binding protein in IgAN pathogenesis, and showed that Gal-3 expression by the kidney was significantly enhanced in patients with IgAN. In both TEPC-15 hybridoma-derived IgA-induced, passive, and spontaneous "grouped" ddY IgAN models, Gal-3 expression was clearly increased with disease severity in the glomeruli, peri-glomerular regions, and some kidney tubules. Gal-3 knockout (KO) in the passive IgAN model had significantly improved proteinuria, kidney function and reduced severity of kidney pathology, including neutrophil infiltration and decreased differentiation of Th17 cells from kidney-draining lymph nodes, despite increased percentages of regulatory T cells. Gal-3 KO also inhibited the NLRP3 inflammasome, yet it enhanced autophagy and improved kidney inflammation and fibrosis. Moreover, administration of 6-de-O-sulfated, N-acetylated low-molecular-weight heparin, a competitive Gal-3 binding inhibitor, restored kidney function and improved kidney lesions in passive IgAN mice. Thus, our results suggest that Gal-3 is critically involved in IgAN pathogenesis by activating the NLRP3 inflammasome and promoting Th17 cell differentiation. Hence, targeting Gal-3 action may represent a new therapeutic strategy for treatment of this kidney disease.
引用
- Chou YL, Chen HL, Hsu BG, et al. Galectin-3 contributes to pathogenesis of IgA nephropathy. Kidney Int. 2024. PMID: 39084257. doi:10.1016/j.kint.2024.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。